While these data may reflect differences in mucosal antibody responses between BNT162b2 mRNA vaccinated and COVID-19 convalescent groups, there was no significant difference in the prevalence of anti-spike IgA or IgG antibodies in saliva between the HIV-1-infected and the HIV-1-uninfected subjects. The gene discussed is CD79A; the disease is COVID-19.